Pharmacological characteristics of brexpiprazole (REXULTI®), a serotonin-dopamine activity modulator
Dr Tetsuro Kikuchi discusses the development of brexpiprazole (REXULTI), a serotonin-dopamine activity modulator used in the treatment of schizophrenia. Dr Kikuchi's insights allow for a deeper understanding of the drug design process, the antipsychotic mode of action of brexpiprazole and its potential position in the treatment of schizophrenia.1
